Disruption of androgen and estrogen receptor activity in prostate cancer by a novel dietary diterpene carnosol: Implications for chemoprevention

Cancer Prevention Research

Volumn 3, Issue 9, 2010, Pages 1112-1123

  Johnson, Jeremy J ^a,c   Syed, Deeba N ^b   Suh, Yewseok ^b   Heren, Chenelle R ^a   Saleem, Mohammad ^b   Siddiqui, Imtiaz A ^b   Mukhtar, Hasan ^b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; CARNOSOL; CASPASE 3; CYCLOHEXIMIDE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FLUTAMIDE; MESSENGER RNA; METRIBOLONE; PROSTATE SPECIFIC ANTIGEN; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL VIABILITY; CHEMOPROPHYLAXIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; MOLECULAR MODEL; MOUSE; NONHUMAN; NUDE MOUSE; PHYTOCHEMISTRY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR BLOCKING; TUMOR XENOGRAFT;

ANDROGEN ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA; CELL LINE, TUMOR; DIET; DITERPENES; DITERPENES, ABIETANE; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; HUMANS; MALE; MICE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77956411543     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-10-0168     Document Type: Article

References (37)

1. Carruba G. Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario. J Cell Biochem 2007;102:899-911. (Pubitemid 350036930)
2. Ellem SJ, Risbridger GP. Treating prostate cancer: a rationale for targeting local oestrogens. Nat Rev Cancer 2007;7:621-7.
3. Heldring N, Pike A, Andersson S, et al. Estrogen receptors: how do they signal and what are their targets. Physiol Rev 2007;87:905-31.
4. Leav I, Merk FB, Kwan PW, Ho SM. Androgen-supported estrogen-enhanced epithelial proliferation in the prostates of intact Noble rats. Prostate 1989;15:23-40.
5. McPherson SJ, Wang H, Jones ME, et al. Elevated androgens and prolactin in aromatase-deficient mice cause enlargement, but not malignancy, of the prostate gland. Endocrinology 2001;142:2458-67.
6. Price D, Stein B, Sieber P, et al. Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial. J Urol 2006;176:965-70, discussion 70-1.
7. Kawashima H, Tanaka T, Cheng JS, et al. Effect of anti-estrogens on the androgen receptor activity and cell proliferation in prostate cancer cells. Urol Res 2004;32:406-10. (Pubitemid 40142616)
8. Bhattacharyya RS, Krishnan AV, Swami S, Feldman D. Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells. Mol Cancer Ther 2006;5:1539-49.
9. Chadha MK, Ashraf U, Lawrence D, et al. Phase II study of fulvestrant (Faslodex) in castration resistant prostate cancer. Prostate 2008;68:1461-6.
10. Masri S, Lui K, Phung S, et al. Characterization of the weak estrogen receptor α agonistic activity of exemestane. Breast Cancer Res Treat 2009;116:461-70.
11. Ariazi EA, Leitao A, Oprea TI, et al. Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen. Mol Cancer Ther 2007;6:2817-27.
12. Huang MT, Ho CT, Wang ZY, et al. Inhibition of skin tumorigenesis by rosemary and its constituents carnosol and ursolic acid. Cancer Res 1994;54:701-8.
13. Aruoma OI, Halliwell B, Aeschbach R, Loligers J. Antioxidant and pro-oxidant properties of active rosemary constituents: carnosol and carnosic acid. Xenobiotica 1992;22:257-68.
14. Aruoma OI, Spencer JP, Rossi R, et al. An evaluation of the antioxidant and antiviral action of extracts of rosemary and Provencal herbs. Food Chem Toxicol 1996;34:449-56.
15. Singletary K, MacDonald C, Wallig M. Inhibition by rosemary and carnosol of 7,12-dimethylbenz[a]anthracene (DMBA)-induced rat mammary tumorigenesis and in vivo DMBA-DNA adduct formation. Cancer Lett 1996;104:43-8. (Pubitemid 126334309)
16. Moran AE, Carothers AM, Weyant MJ, Redston M, Bertagnolli MM. Carnosol inhibits β-catenin tyrosine phosphorylation and prevents adenoma formation in the C57BL/6J/Min/+ (Min/+) mouse. Cancer Res 2005;65:1097-104.
17. 2-phase cell cycle arrest and targets the 5′-AMP-activated protein kinase (AMPK) pathway. Pharm Res 2008;25:2125-34.
18. Lin FM, Tsai CH, Yang YC, et al. A novel diterpene suppresses CWR22Rv1 tumor growth in vivo through antiproliferation and pro-apoptosis. Cancer Res 2008;68:6634-42.
19. Suh Y, Afaq F, Johnson JJ, Mukhtar H. A plant flavonoid fisetin induces apoptosis in colon cancer cells by inhibition of COX2 and Wnt/EGFR/NF-κB- signaling pathways. Carcinogenesis 2009;30:300-7.
20. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989;24:148-54.
21. Nguyen TV, Yao M, Pike CJ. Flutamide and cyproterone acetate exert agonist effects: induction of androgen receptor-dependent neuroprotection. Endocrinology 2007;148:2936-43.
22. Steinsapir J, Mora G, Muldoon TG. Effects of steroidal and nonsteroidal antiandrogens on the androgen binding properties of the rat ventral prostate androgen receptor. Biochim Biophys Acta 1991;1094:103-12.
23. Wilkinson JM, Hayes S, Thompson D, Whitney P, Bi K. Compound profiling using a panel of steroid hormone receptor cell-based assays. J Biomol Screen 2008;13:755-65.
24. Festuccia C, Gravina GL, Muzi P, et al. Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer. Endocr Relat Cancer 2007;14:601-11.
25. Kawata H, Ishikura N, Watanabe M, Nishimoto A, Tsunenari T, Aoki Y. Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity. Prostate 2010;70:745-54.
26. Smith MR, Malkowicz SB, Chu F, et al. Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. J Clin Oncol 2008;26:1824-9.
27. Smith MR. Treatment-related osteoporosis in men with prostate cancer. Clin Cancer Res 2006;12:6315-9s.
28. Fradet Y, Egerdie B, Andersen M, et al. Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study. Eur Urol 2007;52:106-14.
29. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005;26:833-76. (Pubitemid 41428540)
30. Rohrmann S, Nelson WG, Rifai N, et al. Serum estrogen, but not testosterone, levels differ between black and white men in a nationally representative sample of Americans. J Clin Endocrinol Metab 2007;92:2519-25.
31. Smith MR, Malkowicz SB, Chu F, et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol 2008;179:152-5.
32. Boccardo F, Rubagotti A, Battaglia M, et al. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol 2005;23:808-15.
33. Kang IH, Kim HS, Shin JH, et al. Comparison of anti-androgenic activity of flutamide, vinclozolin, procymidone, linuron, and p,p′-DDE in rodent 10-day Hershberger assay. Toxicology 2004;199:145-59.
34. Terada N, Shimizu Y, Yoshida T, et al. Antiandrogen withdrawal syndrome and alternative antiandrogen therapy associated with the W741C mutant androgen receptor in a novel prostate cancer xenograft. Prostate 2010;70:252-61.
35. Yoneya T, Taniguchi K, Nakamura R, et al. Thiochroman derivative CH4986399, a new nonsteroidal estrogen receptor down-regulator, is effective in breast cancer models. Anticancer Res 2010;30:873-8.
36. Yoneya T, Tsunenari T, Taniguchi K, et al. Effects of CH4893237, a new orally active estrogen receptor downregulator, on breast cancer xenograft models with low serum estrogen levels. Oncol Rep 2009;21:747-55.
37. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008;22:659-61. (Pubitemid 351348146)